Compare HD & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HD | AMGN |
|---|---|---|
| Founded | 1978 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.6B | 183.1B |
| IPO Year | 1999 | 2002 |
| Metric | HD | AMGN |
|---|---|---|
| Price | $308.95 | $352.16 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 19 |
| Target Price | ★ $423.00 | $351.05 |
| AVG Volume (30 Days) | ★ 4.6M | 2.0M |
| Earning Date | 05-19-2026 | 04-30-2026 |
| Dividend Yield | 2.89% | ★ 2.98% |
| EPS Growth | N/A | ★ 88.23 |
| EPS | 3.30 | ★ 3.34 |
| Revenue | ★ $66,176,000,000.00 | $25,424,000,000.00 |
| Revenue This Year | $7.13 | $5.00 |
| Revenue Next Year | $4.09 | $2.45 |
| P/E Ratio | ★ $94.03 | $103.42 |
| Revenue Growth | N/A | ★ 8.83 |
| 52 Week Low | $289.10 | $269.77 |
| 52 Week High | $426.75 | $391.29 |
| Indicator | HD | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 63.64 |
| Support Level | $289.10 | $334.95 |
| Resistance Level | $322.10 | $356.53 |
| Average True Range (ATR) | 7.86 | 7.19 |
| MACD | 0.90 | 2.34 |
| Stochastic Oscillator | 61.58 | 90.33 |
Home Depot is the world's largest home improvement specialty retailer, operating 2,359 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the US, Canada, and Mexico. Its stores offer building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of Interline Brands in 2015 allowed Home Depot to enter the MRO business, which has been expanded through the tie-up with HD Supply (2020). The 2024 tie-up with SRS will help grow professional demand in roofing, pool, and landscaping projects, while the 2025 purchase of GMS will lift building product sales through 1,250 distribution locations.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.